ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review.
Rheumatol Int
; 42(4): 749-758, 2022 04.
Article
in English
| MEDLINE | ID: covidwho-1669776
ABSTRACT
For the foreseeable future, vaccines are the cornerstone in the global campaign against the Coronavirus Disease-19 (COVID-19) pandemic. As the number and fatalities due to COVID-19 decline and the lockdown anywise rescinded, we recognize an increase in the incidence of autoimmune disease post-COVID-19 vaccination. However, the causality of the most vaccine-induced side effects is debatable and, at best, limited to a temporal correlation. We herein report a case of a 51-year-old gentleman who developed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis (AAV) 2 week post-COVID-19 vaccination. The patient responded favorably to oral steroids and rituximab. Additionally, we conducted a case-based review of vaccine-associated AAV describing their clinical manifestations and treatment response of this emerging entity.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
/
COVID-19
Type of study:
Case report
/
Observational study
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Rheumatol Int
Year:
2022
Document Type:
Article
Affiliation country:
S00296-021-05069-x
Similar
MEDLINE
...
LILACS
LIS